Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

99
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
99
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

28
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
28
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

30
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
30
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

274
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
274
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

49
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
49
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

386
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update.

Hepatology international·2026
Same author

HbA<sub>1c</sub> trajectories and the risk of liver-related events in patients with type 2 diabetes mellitus.

Journal of hepatology·2026
Same author

Trends in MASLD-related cirrhosis and liver cancer across diverse populations, 2010-2023.

Hepatology international·2026
Same author

Methylation plus alpha-fetoprotein blood test for early detection of HCC in at-risk populations.

Hepatology communications·2026
Same author

HBsAg seroclearance further reduces hepatocellular carcinoma but not hepatic decompensation in patients with cirrhosis and complete viral suppression.

Hepatology (Baltimore, Md.)·2026
Same author

Editorial: Diabetes Management in Cirrhosis-The Window of Opportunity Before Decompensation. Authors' Reply.

Alimentary pharmacology & therapeutics·2026
Same journal

Deescalation, Discontinuation, and Deimplementation Trials: Evaluating Whether and How to Do Less.

JAMA·2026
Same journal

Surgical and Endoscopic Therapies for GERD.

JAMA·2026
Same journal

The Psychedelic Therapies Executive Order: On Approval and Clinical Readiness.

JAMA·2026
Same journal

"Suturing": Love, Death, and Perfection's Limits.

JAMA·2026
Same journal

What Is Low Back Pain?

JAMA·2026
Same journal

From Silicon Valley to the Vatican-The Expanding Debate on AI Ethics.

JAMA·2026
See all related articles

Related Experiment Video

Updated: May 6, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

6.8K

Hepatitis B: A Review.

Wen-Juei Jeng1,2, Terry Cheuk-Fung Yip3,4, Anna S Lok5

  • 1Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Main Branch, Taoyuan, Taiwan.

JAMA
|May 4, 2026
PubMed
Summary
This summary is machine-generated.

Hepatitis B virus (HBV) infection is a major global health concern. Universal HBV vaccination and antiviral therapies are crucial for preventing infection, reducing chronic disease progression, and lowering liver cancer risk.

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

12.9K
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

5.5K

Related Experiment Videos

Last Updated: May 6, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

6.8K
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

12.9K
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

5.5K

Area of Science:

  • Hepatology
  • Virology
  • Public Health

Background:

  • Hepatitis B virus (HBV) infection impacts 254 million globally, causing 1.1 million deaths annually.
  • Mother-to-child transmission is a primary driver of chronic HBV infection worldwide.
  • Low global birth-dose HBV vaccine coverage (45% in 2024) hinders elimination efforts.

Purpose of the Study:

  • To summarize the global impact of HBV infection.
  • To highlight effective prevention and treatment strategies.
  • To underscore the importance of vaccination and antiviral therapy.

Main Methods:

  • Serologic testing (HBsAg, anti-HBs, anti-HBc) for diagnosis.
  • Serum HBV DNA levels for replication assessment.
  • Liver inflammation/fibrosis assessment (ALT, Fibrosis-4, elastography).

Main Results:

  • HBV vaccination and hepatitis B immune globulin prevent ~94% of perinatal infections.
  • Antiviral therapy reduces HBV DNA replication and HCC risk by ~50%.
  • Chronic HBV can progress to cirrhosis (8-15% risk) and HCC (3-5% annual incidence).

Conclusions:

  • Universal birth-dose HBV vaccination is the most effective strategy for HBV elimination.
  • Antiviral therapy is recommended for chronic HBV patients with cirrhosis or high viral load/inflammation.
  • Regular surveillance for HCC in high-risk patients is essential.